Pulmoner Hipertansiyonlu Mitral Kapak Hastalarında İloprost ile ...

42- McLaughlin VV, Genthner DE, Panella MM, Rich S. Reduction in
pulmonary vascular resistance with long-term epoprostenol (prostacyclin)
therapy in primary pulmonary hypertension. N Engl J Med 1998;338:273-7.
43- Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997;336:111-7.
44- Black JM, Denton CP. In Therapy of Systemic Rheumatic Disorders [Eds] van de
Putte LBA, et al. 1997;26:495-531.
45- C.F Opitz, R Wensel, M Bettmann, R Schaffarczyk, M Linscheid , R
Hetzer,R Ewert. Assessment of the vasodilator response in primary
pulmonary hypertension Comparing prostacyclin and iloprost
administered by either infusion or inhalation.European Heart Journel.
2003;49:1076-1080.
46- Fattouch K,Sbraga F, Bianco G, Speziale G,Gucciardo M. Inhaled
prostacyclin, nitrorusside in pulmoner hypertension after mitral valve
replacement. J Card Surg. 2005;20:171-6.
47- Popat KD, Pitt B. Hemodynamic effects of prostaglandin E1 infusion in
patients with acute myocardial infarction and left ventricular failure. Am
Heart J. 1982;103(4 Pt 1):485-9.
48- Tokioka H, Kobayashi O, Ohta Y, Wakabayashi T, Kosaka F. The acute
effects of prostaglandin E1 on the pulmonary circulation and oxygen
delivery in patients with the adult respiratory distress syndrome. Intensive
Care Med. 1985;11(2):61-4.
49- Heerdt PM, Weiss CI. Prostaglandin E1 and intrapulmonary shunt in
cardiac surgical patients with pulmonary hypertension. Ann Thorac Surg.
1990;49:463-5.
50- Leuchte HH, Schwaiblmair M, Baumgartner RA, Neurohr CF, Kolbe T,
Behr J. Hemodynamic response to sildenafil, nitric oxide, and iloprost in
primary pulmonary hypertension. Chest. 2004;125:580-6.
49